Mefenamic Acid: Emerging Evidence & the Future Potential

https://www.meftal.com/clinical-studies

A concise update for healthcare professionals

Introduction

The NLRP3 inflammasome has gained prominence as a key regulator of inflammation across infectious, metabolic and autoimmune diseases. While essential for pathogen defense, its dysregulated activation drives excessive inflammation and tissue damage. This makes NLRP3 an increasingly important therapeutic target.

NLRP3 Inflammasome: Why It Matters Clinically

Activation of the NLRP3 inflammasome leads to caspase1–mediated maturation of IL1β and IL18, resulting in strong inflammatory signaling. Aberrant NLRP3 activation is implicated in: Metabolic disorders; Autoimmune diseases; Tumorigenesis; Viral infections including IAV, DENV, CHIKV, and SARSCoV2.

Role in Pediatric Febrile Seizures

Growing evidence shows elevated NLRP3 and IL1β levels in children with febrile seizures compared to fever-only controls. Key observations: Significant rise in NLRP3 and IL1β (p < 0.05); Strong correlation between IL1β and NLRP3 (r = 0.787; p < 0.001). These findings indicate that the NLRP3/IL1β axis contributes to seizure susceptibility and may serve as a biomarker or therapeutic target.

Mefenamic Acid: The Only NSAID That Inhibits NLRP3

Uniquely among NSAIDs, mefenamic acid inhibits the NLRP3 inflammasome, independent of COX inhibition. This dual mechanism enables: Reduction of fever and pain (via COX blockade); Suppression of IL1β overproduction (via NLRP3 inhibition).

Clinical Implications

In Pediatrics: For febrile seizures—with documented elevation of NLRP3 and IL1β—mefenamic acid may offer additional benefit by modulating inflammasome-driven neuroinflammation. In Viral Illnesses: Since many pediatric viral infections activate NLRP3, mefenamic acid’s ability to dampen inflammasome activity may help reduce inflammation-driven complications.

Future Outlook

Emerging evidence suggests potential future roles for mefenamic acid in: Febrile seizure management; Viral infection–related inflammation; Immune and metabolic disorders with NLRP3 hyperactivation. Ongoing research will further clarify the scope of these applications.

Reference: Pai U, Venkata R A, Shah A, et al. Cureus. 2025; 17(7) : 1-19

Products:

MEFTAL-P Suspension is indicated for the symptomatic treatment of fever in children above 6 months of age.

URL Reference:  https://www.meftal.com/product/meftal-p-mefenamic-acid-suspension